-
Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 Clinical Trial Optional)
(PA-20-141)
National Institute of Mental Health
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below
-
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)
(PA-20-142)
National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of General Medical Sciences
National Cancer Institute
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Environmental Health Sciences
National Eye Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute of Mental Health
National Institute of Nursing Research
National Center for Complementary and Integrative Health
National Institute of Biomedical Imaging and Bioengineering
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Application Receipt Date(s): Standard dates apply
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Center of Excellence for Research on Complementary and Integrative Health (P01,Clinical Trial Optional)
(PAR-20-138)
National Center for Complementary and Integrative Health
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is May 25, 2020.
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
(PAR-20-140)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): Standard dates apply.
-
Firearm Injury and Mortality Prevention Research (R61 Clinical Trial Optional)
(PAR-20-143)
Office of Behavioral and Social Sciences Research
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Institute on Drug Abuse
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Center for Complementary and Integrative Health
Office of Research on Women's Health
Office of Disease Prevention
National Institute on Minority Health and Health Disparities
Application Receipt Date(s): May 15, 2020
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional)
(RFA-CA-20-027)
National Cancer Institute
Application Receipt Date(s): July 31, 2020; July 30, 2021
-
Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)
(RFA-CA-20-028)
National Cancer Institute
Application Receipt Date(s): July 31, 2020; July 30, 2021
-
Patient-oriented Research to Mitigate Health Disparities and Lessen the Burden of Chronic Diseases Within the Mission of NIDDK (R01 Clinical Trial Optional)
(RFA-DK-20-015)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): May 22, 2020
No late applications will be accepted for this Funding Opportunity Announcement.
-
Genomic Predictors of Pregnancy Loss (R01 Clinical Trial Not Allowed)
(RFA-HD-21-005)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Human Genome Research Institute
Application Receipt Date(s): July 30, 2020
-
Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)
(RFA-HG-20-014)
National Human Genome Research Institute
Application Receipt Date(s): June 24, 2020; March 9, 2021; February 4, 2022
-
Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)
(RFA-HG-20-015)
National Human Genome Research Institute
Application Receipt Date(s): June 24, 2020; March 9, 2021; February 4, 2022
-
Novel Synthetic Nucleic Acid Technology Development (R43/R44)( Clinical Trial not allowed)
(RFA-HG-20-016)
National Human Genome Research Institute
National Center for Advancing Translational Sciences
National Center for Advancing Translational Sciences
Application Receipt Date(s): June 24, 2020; March 9, 2021; February 4, 2022
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.